I

think it is a very effective regimen.

It's a harder regimen.

And they've now moved on in a good way from Beacop.

And I will say the one good thing about Beacop, even for like Nevo AVD or ABVD advocates, is the way they've designed it, even before targeted agents, that for many patients, just with chemo, you only need four cycles.

And when you think about things like cumulative anthracycline matters, how much, not just do you get it, but how much, how long, or other medications.

And what they've now done is they've not integrated immunotherapy yet.

So how are you currently following patients post-chemotherapy to evaluate for the possibility or risk of recurrence? Yeah,